A case study from the University of Colorado suggests that traditional gene testing for NSCLC patients may not be sufficient for detecting potential oncogenic drivers.
The phase III ALCYONE study showed that daratumumab in combination with bortezomib, melphalan, and prednisone is a viable front-line option for myeloma patients who are not candidates for ASCT.
A recent study suggests that next-generation sequencing of circulating tumor DNA is feasible in carcinoma of unknown primary, which could facilitate targeted therapy for this hard-to-treat disease.
Circulating tumor cells isolated from early stages of lung cancer may be predictive of poor prognosis and could potentially be predictive biomarkers of disease recurrence.
Researchers have discovered a three-drug combo that may combat acute lymphoblastic leukemia by shutting down the production of nucleotides that activate a DNA replication stress response.
Researchers at St. Jude Children’s Research Hospital have discovered a vulnerability that may easily translate into new targeted drug therapies that block heme biosynthesis, killing leukemic cells.
A new study has shown that it may now be possible to predict survival outcomes and patients’ response to chemotherapy based on the molecular classification of four distinct subtypes of gastric cancer.
ASCO is issuing a new clinical practice guideline that clarifies the role of immunotherapy in the treatment of patients with advanced non–small-cell lung cancer.
